Description
The 3A2-2E7 monoclonal antibody (also known as SN8) specifically recognizes CD79b. Immunoglobulin (Ig) antigen receptors are composed of a non-covalently-associated complex of Ig and two other proteins, Igα and Igβ, clustered as CD79a and CD79b, respectively. CD79b is a membrane glycoprotein of 229 residues, with a predicted relative molecular mass of 36-40 kDa. Its expression is restricted to B lineage cells. CD79b reportedly associates with surface IgM and is involved in signal transduction. The 3A2-2E7 antibody has similar reactivity characteristics as clone CB3-1. The 3A2-2E7 and CD3-1 antibodies specifically react with an epitope that is enhanced on certain B-cell leukemias such as prolymphocytic leukemia and lymphoma, but not on chronic lymphocytic leukemia.
Put all BD® AbSeq Reagents to be pooled into a Latch Rack for 500 µL Tubes (Thermo Fisher Scientific Cat. No. 4900). Arrange the tubes so that they can be easily uncapped and re-capped with an 8-Channel Screw Cap Tube Capper (Thermo Fisher Scientific Cat. No. 4105MAT) and the reagents aliquoted with a multi-channel pipette. BD® AbSeq tubes should be centrifuged for ≥ 30 seconds at 400 × g to ensure removal of any content in the cap/tube threads prior to the first opening.
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography and conjugated to BD® AbSeq oligonucleotide under optimal conditions.
1. This reagent has been pre-diluted for use at the recommended volume per test. Typical use is 2 µl for 1 × 10^6 cells in a 200-µl staining reaction.
2. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
4. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
5. Illumina is a trademark of Illumina, Inc.
6. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
7. Please refer to bd.com/genomics-resources for technical protocols.
8. For U.S. patents that may apply, see bd.com/patents.
